JP5138603B2 - システアミン化合物を用いてウイルス感染を治療するための材料および方法 - Google Patents

システアミン化合物を用いてウイルス感染を治療するための材料および方法 Download PDF

Info

Publication number
JP5138603B2
JP5138603B2 JP2008542483A JP2008542483A JP5138603B2 JP 5138603 B2 JP5138603 B2 JP 5138603B2 JP 2008542483 A JP2008542483 A JP 2008542483A JP 2008542483 A JP2008542483 A JP 2008542483A JP 5138603 B2 JP5138603 B2 JP 5138603B2
Authority
JP
Japan
Prior art keywords
cysteamine
influenza
virus
infection
influenza virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008542483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517395A5 (https=
JP2009517395A (ja
Inventor
ハオ イ リン
フランシス チ
キンフ スー
ビル ピウ チャン
Original Assignee
オメガ バイオ−ファルマ （エイチ．ケイ．） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オメガ バイオ−ファルマ （エイチ．ケイ．） リミテッド filed Critical オメガ バイオ−ファルマ （エイチ．ケイ．） リミテッド
Publication of JP2009517395A publication Critical patent/JP2009517395A/ja
Publication of JP2009517395A5 publication Critical patent/JP2009517395A5/ja
Application granted granted Critical
Publication of JP5138603B2 publication Critical patent/JP5138603B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2008542483A 2005-11-28 2006-11-28 システアミン化合物を用いてウイルス感染を治療するための材料および方法 Expired - Fee Related JP5138603B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US74058405P 2005-11-28 2005-11-28
US60/740,584 2005-11-28
US81077306P 2006-06-02 2006-06-02
US60/810,773 2006-06-02
US81888506P 2006-07-06 2006-07-06
US60/818,885 2006-07-06
US84702006P 2006-09-25 2006-09-25
US60/847,020 2006-09-25
PCT/US2006/045652 WO2007062272A1 (en) 2005-11-28 2006-11-28 Materials and methods for treating viral infections with a cysteamine compound

Publications (3)

Publication Number Publication Date
JP2009517395A JP2009517395A (ja) 2009-04-30
JP2009517395A5 JP2009517395A5 (https=) 2010-01-07
JP5138603B2 true JP5138603B2 (ja) 2013-02-06

Family

ID=37769370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542483A Expired - Fee Related JP5138603B2 (ja) 2005-11-28 2006-11-28 システアミン化合物を用いてウイルス感染を治療するための材料および方法

Country Status (20)

Country Link
US (2) US8415398B2 (https=)
EP (1) EP1954258B8 (https=)
JP (1) JP5138603B2 (https=)
KR (1) KR101440629B1 (https=)
CN (1) CN102038667A (https=)
AP (1) AP2877A (https=)
AR (1) AR057623A1 (https=)
AU (1) AU2006318355B2 (https=)
BR (1) BRPI0619377A2 (https=)
CA (1) CA2631241C (https=)
DK (1) DK1954258T3 (https=)
ES (1) ES2392976T3 (https=)
IL (1) IL191705A (https=)
MX (1) MX2008006851A (https=)
MY (1) MY141003A (https=)
NZ (1) NZ568464A (https=)
PL (1) PL1954258T3 (https=)
PT (1) PT1954258E (https=)
TW (1) TWI401079B (https=)
WO (1) WO2007062272A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067899A2 (en) * 2004-01-13 2005-07-28 Omega Bio-Pharma (I.P.2) Limited Methods for treating stress and affecting biological immune systems using a cysteamine compound
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
EP3659588A1 (en) 2006-01-27 2020-06-03 The Regents of The University of California Enterically coated cysteamine and salts thereof
CN101842092A (zh) * 2007-05-25 2010-09-22 奥碧医药(香港)有限公司 用于治疗流感感染的材料和方法
US20120058937A9 (en) * 2008-04-15 2012-03-08 Tsrl, Inc. Prodrugs of Neuraminidase Inhibitors
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
WO2010138419A2 (en) * 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
US20120308608A1 (en) * 2010-02-01 2012-12-06 Megan Shaw Interferon-inducing compounds and uses thereof
NZ603040A (en) * 2010-04-15 2015-03-27 Biota Scient Management Compound for treatment of respiratory condition or disease
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
WO2015038655A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
WO2016145103A1 (en) 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
JP7418958B2 (ja) 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
GB201609940D0 (en) 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
US11758928B2 (en) 2016-12-15 2023-09-19 Société des Produits Nestlé S.A. Compositions and methods that modulate phosphorus or enzymes in a companion animal
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
EP3866775B1 (en) 2018-10-17 2025-03-19 Novabiotics Limited Cysteamine for use in the treatment of lung diseases
US20230218571A1 (en) * 2020-04-01 2023-07-13 Thiogenesis Therapeutics, Inc. Cysteamine precursor compounds for the treatment of betacoronavirus infections
CA3176642A1 (en) 2020-05-13 2021-11-18 Regents Of The University Of Michigan Cysteamine for the treatment of sars-cov-2 infection
JP2023527038A (ja) * 2020-05-25 2023-06-26 ノバビオティクス・リミテッド 抗ウイルス治療
WO2022040045A1 (en) * 2020-08-18 2022-02-24 New Amsterdam Sciences, Inc. Sod mimetic and methods of using same for the treatment of covid-19
EP4444323A4 (en) * 2021-12-07 2025-12-03 Cila Therapeutic Inc ANTIVIRAL THERAPEUTIC AGENTS AND THEIR USES
WO2024009307A1 (en) * 2022-07-06 2024-01-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Viroporins blockers/inhibitors as anti-flaviviruses agents

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152180A (en) 1960-08-25 1964-10-06 Studiengesellschaft Kohle Mbh Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3538160A (en) 1965-03-24 1970-11-03 Smithkline Corp Pentacyclooctaneamines
US3483254A (en) 1967-01-03 1969-12-09 Merck & Co Inc 2-bornanemethylamines
US3496228A (en) 1967-02-16 1970-02-17 Smithkline Corp Aminotricyclononanes and the salts thereof
US3534084A (en) 1968-10-16 1970-10-13 Squibb & Sons Inc Adamantylamino-naphthyloxypropanols and related compounds
US3592934A (en) 1969-06-20 1971-07-13 Du Pont Pharmaceutical compositions and methods of controlling influenza a virus infection utilizing substituted adamantanes and tricyclo(4.3.1.13.8) undecanes
IT1055560B (it) * 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
ES2027527A6 (es) 1990-12-17 1992-06-01 Andromaco Lab Procedimiento para la obtencion de polimeros dotados de actividad antiviral.
DE4103177A1 (de) 1991-02-02 1992-08-06 Boehringer Mannheim Gmbh Thiazolo-(2,3-a)isoindol-derivate und diese enthaltende arzneimittel
US5314917A (en) * 1991-03-22 1994-05-24 E. B. Michaels Research Associates, Inc. Method for inactivating enveloped viruses and sperm
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
PT100914A (pt) * 1991-09-30 1993-10-29 Jess G Thoene Uso de compostos capazes de sofrer uma permuta mista com dissulfureto, com uma ligacao dissulfureto, no tratamento de infeccao por hiv
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
EP0789565A4 (en) * 1993-10-15 1999-03-24 Jess G Thoene PREVENTION OF HIV INFECTION
US5725870A (en) * 1993-10-15 1998-03-10 Thoene; Jess G. Methods, composites and articles for contraception
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5684024A (en) 1996-01-25 1997-11-04 Viropharma Incorporated Pyrazole dimers compositions and methods for treating influenza
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
CA2326771A1 (en) * 1998-03-30 1999-10-07 Endowment For Research In Human Biology, Inc. (The) Agents and methods for modulation of zinc transfer by metallothionein
DE19817511A1 (de) * 1998-04-20 1999-10-21 Werner Slenczka Antivirale Wirksamkeit der Pantothensäure, des Dexpanthenols und ihrer Derivate. Hemmwirkung auf die Virusreplikation umhüllter Viren durch Blockade des Fusionsvorgangs.
US6063383A (en) * 1999-01-28 2000-05-16 Hsu; Wu-Ching Pharmaceutical suppository composites for fever and influenza and method of producing the composites
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
RU2175230C1 (ru) 2001-01-23 2001-10-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с противовирусной активностью и способ ее получения
CA2445512C (en) * 2001-04-25 2010-10-12 Cobalz Limited A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method
GB2377874B (en) * 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US20060211748A1 (en) * 2002-07-11 2006-09-21 Bain Allen I Sulphydryl compounds in combination with sulpha compounds
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
AU2003900064A0 (en) * 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US20040191295A1 (en) * 2003-03-28 2004-09-30 Locniskar Mary Frances Composition and method for viral inhibition
DE10340845A1 (de) * 2003-09-04 2005-03-31 Flavin-Koenig, Dana F., Dr. Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales

Also Published As

Publication number Publication date
HK1123726A1 (en) 2009-06-26
US20070135525A1 (en) 2007-06-14
AR057623A1 (es) 2007-12-05
EP1954258B1 (en) 2012-09-05
TWI401079B (zh) 2013-07-11
AP2008004511A0 (en) 2008-06-30
CA2631241C (en) 2014-02-11
KR20080077658A (ko) 2008-08-25
ES2392976T3 (es) 2012-12-17
CA2631241A1 (en) 2007-05-31
NZ568464A (en) 2010-09-30
WO2007062272A1 (en) 2007-05-31
CN102038667A (zh) 2011-05-04
TW200733953A (en) 2007-09-16
US9283198B2 (en) 2016-03-15
AP2877A (en) 2014-03-31
DK1954258T3 (da) 2012-10-15
MX2008006851A (es) 2008-10-09
BRPI0619377A2 (pt) 2011-09-27
US8415398B2 (en) 2013-04-09
IL191705A (en) 2013-11-28
JP2009517395A (ja) 2009-04-30
AU2006318355A1 (en) 2007-05-31
PL1954258T3 (pl) 2013-01-31
KR101440629B1 (ko) 2014-09-15
EP1954258A1 (en) 2008-08-13
US20130338113A1 (en) 2013-12-19
AU2006318355B2 (en) 2012-01-12
IL191705A0 (en) 2009-02-11
EP1954258B8 (en) 2012-10-10
MY141003A (en) 2010-02-12
PT1954258E (pt) 2012-10-22

Similar Documents

Publication Publication Date Title
JP5138603B2 (ja) システアミン化合物を用いてウイルス感染を治療するための材料および方法
US20120129946A1 (en) Materials and methods for treating viral infections
JP2019510044A (ja) ウイルス感染症の治療用チアゾリド化合物
WO2013044871A1 (zh) 氯喹或氯丙嗪或其衍生物或它们的混合物在制备用于治疗和/或预防肺感染和损伤的药物中的用途
JP2010528053A (ja) インフルエンザ感染症を治療するための物質および方法
CN101340902B (zh) 用半胱胺化合物处理病毒感染的材料和方法
ES2937145T3 (es) Azelastina como tratamiento antiviral
RU2431476C2 (ru) Материалы и способы лечения вирусных инфекций с помощью соединения цистеамина
HK1123726B (en) Materials and methods for treating viral infections with a cysteamine compound
CN100562342C (zh) 防治流感病毒感染的寡核苷酸药物
CN104857007A (zh) 一种流感病毒神经氨酸酶的新型抑制剂及其用途
US20240075012A1 (en) Compositions and methods for treating viral infection
CN113730584B (zh) 双硫仑联合铜补充剂在制备抗rna病毒的药物中的应用
WO2024027844A1 (zh) 一种药物组合物及其用途
CN108721264B (zh) 异克舒令在制备治疗或预防流感病毒感染的药物中的应用
WO2026026100A1 (zh) 安石榴苷的抗病毒用途
HK40068775B (zh) 法匹拉韦在制备预防或治疗冠状病毒感染性疾病药物中的应用
BRPI0705586B1 (pt) uso de antagonistas do receptor fator de ativação plaquetária para o tratamento infecções causadas pelo vírus influenza
JP2004352712A (ja) インフルエンザの予防または治療剤
JPWO2023283586A5 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121022

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121114

R150 Certificate of patent or registration of utility model

Ref document number: 5138603

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151122

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees